Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

In 2017, GlaxoSmithKline announced its intention to withdraw the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons. This announcement came before the emergence of definitive evidence regarding the cardiovascular safety and efficacy of albiglutide. In The Lancet, Adrian Hernandez and colleagues1 report results from the Harmony Outcomes trial, which showed, in 9463 participants, that albiglutide has beneficial effects on cardiovascular outcomes when given to people with type 2 diabetes and atherosclerotic cardiovascular disease.